Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms

Abstract

BACKGROUND.The behavior of neuroendocrine neoplasms is poorly defined, and predictors of outcome after surgical resection have yet to be identified. Consequently, guidelines for treatment remain unclear. Current pathologic classification systems do not permit meaningful discrimination of hepatic neuroendocrine neoplasms.METHODS.The authors reviewed prospectively maintained databases from 2 institutions of patients who underwent hepatic resection for neuroendocrine neoplasms between 1990 and 2006. Patient, tumor, and operative characteristics were analyzed to identify factors associated with overall survival, progression‐free survival, and symptom control. Hepatic neoplasms were stratified by using a 3‐tier pathologic classification system based on the number of mitotic figures and the presence of tumor necrosis that was recently validated for pancreatic neuroendocrine neoplasms.RESULTS.Seventy patients were identified from the databases. Low‐grade, intermediate‐grade, and high‐grade neoplasms were identified in 53%, 37%, and 10% of patients, respectively. After a median follow‐up of 51 months, the median overall survival for all patients was 91 months, and it was 108 months when 7 patients with high‐grade neuroendocrine carcinomas were excluded. Progressive disease was eventually observed in 81% of patients, and the median progression‐free survival was 17 months. The median time to the onset of symptoms was 39 months for patients who presented with hormonal symptoms and 80 months for all patients. Histologic grade was associated with poorer overall and progression‐free survival.CONCLUSIONS.When performed in a context of aggressive multimodality therapy, long‐term outcomes after partial hepatectomy for hepatic neuroendocrine neoplasms were favorable; however, disease progression was eventually observed in the majority of patients. Several oncologic variables were associated with significant differences in survival after resection. A novel pathologic classification system appears to enhance prognostic stratification of patients with hepatic neuroendocrine neoplasms. Cancer 2008. © 2008 American Cancer Society.

Neuroendocrine tumor disease: an evolving landscape

“…Irrespective of the primary tumor site and in absence of nonresectable extrahepatic disease, surgery should therefore be proposed in all well-differentiated GEP-NEN patients with LM in whom complete resection is feasible. It should be noted that individuals with highgrade NENs probably represent a separate disease entity and are unsuitable for surgical treatment as they exhibit a median overall survival of only 6 months after partial hepatectomy (Cho et al 2008). It is therefore critical that a core needle biopsy or laparoscopically guided biopsy is undertaken before the decision for surgery to establish tumor grading.…”

Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin

“…Various groups have reported impressive 5-year survival rates up to 87% following surgical resection of NET liver metastases (Que et al 1995, Chamberlain et al 2000, Nave et al 2001, Musunuru et al 2006. Unfortunately recurrence is observed in the majority of patients (Cho et al 2008). For some patients, subtotal resection of the bulk of tumour may be appropriate for palliation of symptomatic recurrence from local effects or hormone secretion (Sarmiento et al 2003).…”

Resection of liver metastasis from neuroendocrine tumors: evaluation of results and prognostic factors

“…Several studies have demonstrated adverse movement in neuroendocrine tumors originating in the pancreas 3,17, . Patients with liver metastases from TNE have high recurrence rate 28,[30][31][32] and less than 15% are cured 6,13 . In this study, relapse occurred in 46.1% of patients who underwent complete resection of liver metastases.…”